Letter to the Editor: Comment on "Evaluating the Efficacy of Intratympanic Dexamethasone in Protecting Against Irreversible Hearing Loss in Patients on Cisplatin-Based Cancer Treatment: A Randomized Controlled Phase IIIB Clinical Trial" (Moreno and Belinchon 2022)

Avi Shupak

doi:10.1097/aud.0000000000001209

Letter to the Editor: Comment on "Evaluating the Efficacy of Intratympanic Dexamethasone in Protecting Against Irreversible Hearing Loss in Patients on Cisplatin-Based Cancer Treatment: A Randomized Controlled Phase IIIB Clinical Trial" (Moreno and Belinchon 2022)

Department of Communication Sciences and Disorders

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	1086-1087
Number of pages	2
Journal	Ear and Hearing
Volume	43
Issue number	3
DOIs	https://doi.org/10.1097/aud.0000000000001209
State	Published - 8 May 2022

ASJC Scopus subject areas

Otorhinolaryngology
Speech and Hearing

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/aud.0000000000001209

Cite this

@article{61daeff3db5c4812b87d9c4bcd4950ca,

title = "Letter to the Editor: Comment on {"}Evaluating the Efficacy of Intratympanic Dexamethasone in Protecting Against Irreversible Hearing Loss in Patients on Cisplatin-Based Cancer Treatment: A Randomized Controlled Phase IIIB Clinical Trial{"} (Moreno and Belinchon 2022)",

author = "Avi Shupak",

year = "2022",

month = may,

day = "8",

doi = "10.1097/aud.0000000000001209",

language = "English",

volume = "43",

pages = "1086--1087",

journal = "Ear and Hearing",

issn = "0196-0202",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "3",

}

Shupak, A 2022, 'Letter to the Editor: Comment on "Evaluating the Efficacy of Intratympanic Dexamethasone in Protecting Against Irreversible Hearing Loss in Patients on Cisplatin-Based Cancer Treatment: A Randomized Controlled Phase IIIB Clinical Trial" (Moreno and Belinchon 2022)', Ear and Hearing, vol. 43, no. 3, pp. 1086-1087. https://doi.org/10.1097/aud.0000000000001209

Letter to the Editor: Comment on "Evaluating the Efficacy of Intratympanic Dexamethasone in Protecting Against Irreversible Hearing Loss in Patients on Cisplatin-Based Cancer Treatment: A Randomized Controlled Phase IIIB Clinical Trial" (Moreno and Belinchon 2022). / Shupak, Avi.
In: Ear and Hearing, Vol. 43, No. 3, 08.05.2022, p. 1086-1087.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Letter to the Editor

T2 - Comment on "Evaluating the Efficacy of Intratympanic Dexamethasone in Protecting Against Irreversible Hearing Loss in Patients on Cisplatin-Based Cancer Treatment: A Randomized Controlled Phase IIIB Clinical Trial" (Moreno and Belinchon 2022)

AU - Shupak, Avi

PY - 2022/5/8

Y1 - 2022/5/8

UR - http://www.scopus.com/inward/record.url?scp=85128488892&partnerID=8YFLogxK

U2 - 10.1097/aud.0000000000001209

DO - 10.1097/aud.0000000000001209

M3 - Letter

C2 - 35298115

AN - SCOPUS:85128488892

SN - 0196-0202

VL - 43

SP - 1086

EP - 1087

JO - Ear and Hearing

JF - Ear and Hearing

IS - 3

ER -

Letter to the Editor: Comment on "Evaluating the Efficacy of Intratympanic Dexamethasone in Protecting Against Irreversible Hearing Loss in Patients on Cisplatin-Based Cancer Treatment: A Randomized Controlled Phase IIIB Clinical Trial" (Moreno and Belinchon 2022)

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this